Statistical Analysis Plan

<table>
<thead>
<tr>
<th>TRIAL FULL TITLE</th>
<th>Doravirine concentrations and antiviral activity in genital fluids in HIV-1 infected individuals (“DORAGEN Study”)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAP VERSION</td>
<td>1.0</td>
</tr>
<tr>
<td>SAP VERSION DATE</td>
<td>06/05/2019</td>
</tr>
<tr>
<td>Protocol Version (SAP associated with)</td>
<td>1.2</td>
</tr>
</tbody>
</table>

**Principal Investigator**

Daniel Podzamczer, M.D, PhD.

HIV and STD Unit - Infectious Diseases Department

Hospital Universitari de Bellvitge

**Author**

Antonio Navarro, MSc

HIV and STD Unit - Infectious Diseases Department

Hospital Universitari de Bellvitge

**Protocol identification number:** DORAGEN

**ClinicalTrials.gov Identifier:** NCT04097925
Signature page

Principal investigator: Daniel Podzamczer (06/05/2019)

Author: Antonio Navarro (06/05/2019)
**Abbreviations**

HIV   Human Immunodeficiency Virus  
TAF   Tenofovir Alafenamide Fumarate  
FTC   Emtricitabine  
ART   Antiretroviral Treatment  
PK    Pharmacokinetics  
PD    Pharmacodynamics
Table of contents

1. Introduction ........................................................................................................... 5
2. Study Design........................................................................................................... 5
3. Aims and Objectives ............................................................................................. 6
4. Outcomes .............................................................................................................. 6
5. Population to be analyzed ..................................................................................... 6
6. Analyses ................................................................................................................. 6
7. Missing data .......................................................................................................... 6
1. Introduction

The aim of this project is to assess Doravirine concentrations in seminal plasma and cervicovaginal fluid in HIV-1 infected male and female individuals receiving ART with Doravirine plus TAF/FTC.

This statistical analysis plan (SAP) will give more detailed descriptions of the endpoints in the study and the corresponding analyses.

2. Study Design

Study subjects will be selected from the routine control visits in the outpatient clinic of the HIV and STD Unit at the Bellvitge University Hospital. Asymptomatic, HIV-1 infected individuals and be on stable ART continuously or ≥3 consecutive months and Plasma HIV-1 RNA at <40 copies/mL for at least 3 months will be recruited.

This is Pilot study, Open label, single arm, single center, prospective study. Study patients will receive one tablet of Doravirine 100 mg administered in combination with FTC and TAF (Descovy®).

Clinic visits will be performed at 3 time points: baseline, week 4 and week 8, only in baseline and w8 HIV-1 RNA viral load and Doravirine cervicovaginal fluid and seminal plasma concentration will be assessed.

2.1 Sample Size.

Fifteen male and fifteen female individuals will be included in the study. This is a study designed to obtain information about doravirine concentrations and HIV viral suppression in seminal plasma and cervicovaginal fluid. The study design is similar to other studies evaluating PK and PD of antiretroviral drugs in these compartments.
3. Aims and Objectives
This study will address these unknowns and provide additional evidence for the scientific rational for the use of Doravirine in treatment and prevention strategies.

4. Outcomes
- Concentration of Doravirine in seminal plasma and cervicovaginal fluid in HIV-1 infected male and female individuals, respectively, 8 weeks after switching to Doravirine plus TAF/FTC.
- HIV-1 RNA in seminal plasma and cervicovaginal fluid in HIV-1 infected male and female individuals, respectively, 8 weeks after switching to Doravirine plus TAF/FTC.

4.1 Safety outcomes

Adverse events
Adverse events are reported at each clinic visit.

Concomitant medications
Usage of medications during study period will be recorded.

5. Population to be analyzed

Per Protocol (PP)
All randomised study subjects completing the whole study period (complete cases). For a specific analysis, study subjects with missing data on any of the variables in the model will be excluded from the analysis.

6. Analyses
All outcomes will be presented using descriptive statistics; normally distributed data by the mean and standard deviation (SD) and skewed distributions by the median and interquartile range (IQR). Binary and categorical variables will be presented using counts and percentages.

The primary analysis will determine the Doravirine concentration in cervicovaginal fluid and seminal plasma and blood plasma, and the HIV-1 viral load in cervicovaginal fluid and seminal plasma and blood plasma.

7. Missing data
Subjects with missing data will be excluded for the analysis.